This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Q2 FY27 consolidated revenue down 29.8% to Rs 42,473 million from Rs 60,469 million last year
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated Q2 FY27 revenue was Rs 42,473 million, down 29.8% from Rs 60,469 million in Q2 FY26. Profit after tax was Rs 2,638 million, adjusted profit after tax Rs 4,852 million and EBITDA Rs 8,638 million, with a 20.3% EBITDA margin. Comparable revenue rose about 20% excluding out-licensing effects, led by 31% core growth in North America and 33.2% in Emerging Markets. H1 FY27 revenue was Rs 82,658 million, down 11.2%.
The reported revenue fall may pressure the stock, while 20% comparable revenue growth, positive profit and regional strength support the outlook.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹4,157 Cr | ₹6,047 Cr | −31.3% |
| Operating profit | ₹529.4 Cr | ₹2,152 Cr | −75.4% |
| Profit after tax | ₹263.8 Cr | ₹610.4 Cr | −56.8% |
| EBITDA margin | 11.8% | 16.1% | −4.3 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.